Advertisement Vela, Protagen sign agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Vela, Protagen sign agreement

Vela Laboratories and Protagen, an in-vitro diagnostics and GMP-compliant protein analysis provider, have entered into customer based analytics, sales and marketing deal.

Austria-based Vela offers research activities to clinical phases and up to product commercialization to its customers.

VELA CEO Markus Fido said their customers will benefit from this alliance through more efficient project work and study design.

Protagen CEO Stefan Mullner said their customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio.